Literature DB >> 22664309

Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.

Joseph C Ratliff1, Laura B Palmese, Erin L Reutenauer, Vinod H Srihari, Cenk Tek.   

Abstract

BACKGROUND: Individuals with schizophrenia have a life expectancy that is 20 years less than the general population, along with high rates of obesity and cardiovascular disease (CVD) mortality.
OBJECTIVE: This study assessed the 10-year general CVD risk and vascular ages of 106 obese schizophrenia spectrum patients and 197 demographically matched obese controls without severe mental illness (SMI) from the National Health and Nutrition Examination Survey (NHANES).
METHODS: Vascular age and general CVD risk were calculated using the Framingham global CVD calculator, which incorporates age, sex, total and HDL cholesterol levels, systolic blood pressure, smoking status, and diabetes or hypertension treatment.
RESULTS: Obese schizophrenia spectrum patients had a mean vascular age that was 14.1 years older than their mean actual age, whereas obese NHANES participants had only a 6.7-year difference. The probability of experiencing a CVD event within the next 10 years was 10.7% for obese patients and 8.5% for obese NHANES participants.
CONCLUSION: These findings suggest that schizophrenia spectrum patients experience increased metabolic risk independent of weight. Primary care clinicians can utilize general CVD risk and vascular age scores to communicate metabolic risk more easily and to help make treatment decisions.
Copyright © 2013 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22664309      PMCID: PMC3435456          DOI: 10.1016/j.psym.2012.03.001

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  37 in total

1.  Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.

Authors:  Rod Jackson; Carlene M M Lawes; Derrick A Bennett; Richard J Milne; Anthony Rodgers
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

2.  Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.

Authors:  Jun Soo Kwon; Jung-Seok Choi; Won-Myoung Bahk; Chang Yoon Kim; Chan Hyung Kim; Young Chul Shin; Byung-Joo Park; Chang Geun Oh
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 3.  Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.

Authors:  Viktoria Simon; Ruud van Winkel; Marc De Hert
Journal:  J Clin Psychiatry       Date:  2009-07       Impact factor: 4.384

4.  Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

Authors:  Julio Bobes; Celso Arango; Pedro Aranda; Rafael Carmena; Margarida Garcia-Garcia; Javier Rejas
Journal:  Schizophr Res       Date:  2006-11-21       Impact factor: 4.939

5.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 6.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

7.  The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year.

Authors:  S G Schorr; C J Slooff; R Bruggeman; K Taxis
Journal:  J Psychiatr Res       Date:  2009-04-26       Impact factor: 4.791

8.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

9.  Obesity in adulthood and its consequences for life expectancy: a life-table analysis.

Authors:  Anna Peeters; Jan J Barendregt; Frans Willekens; Johan P Mackenbach; Abdullah Al Mamun; Luc Bonneux
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

Review 10.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Authors:  M John Chapman; Henry N Ginsberg; Pierre Amarenco; Felicita Andreotti; Jan Borén; Alberico L Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Børge G Nordestgaard; Kausik K Ray; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen; Gerald F Watts
Journal:  Eur Heart J       Date:  2011-04-29       Impact factor: 29.983

View more
  17 in total

1.  The prevalence and independent influencing factors of obesity and underweight in patients with schizophrenia: a multicentre cross-sectional study.

Authors:  Juan Wang; Yulong Zhang; Yating Yang; Zhiwei Liu; Lei Xia; Wenzheng Li; Zhongxiang Li; Xinhui Xie; Wenfeng Deng; Kai Zhang; Huanzhong Liu
Journal:  Eat Weight Disord       Date:  2020-06-17       Impact factor: 4.652

2.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

3.  Using Smartphone Apps to Promote Psychiatric and Physical Well-Being.

Authors:  Cathaleene Macias; Trishan Panch; Yale M Hicks; Jason S Scolnick; David Lyle Weene; Dost Öngür; Bruce M Cohen
Journal:  Psychiatr Q       Date:  2015-12

4.  Physical health indicators in major mental illness: analysis of QOF data across UK general practice.

Authors:  Julie Langan Martin; Richard Lowrie; Alex McConnachie; Gary McLean; Frances Mair; Stewart W Mercer; Daniel J Smith
Journal:  Br J Gen Pract       Date:  2014-10       Impact factor: 5.386

Review 5.  Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.

Authors:  Cenk Tek; Suat Kucukgoncu; Sinan Guloksuz; Scott W Woods; Vinod H Srihari; Aniyizhai Annamalai
Journal:  Early Interv Psychiatry       Date:  2015-05-12       Impact factor: 2.732

6.  Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses.

Authors:  Brian J Miller; Prianka Kandhal; Mark Hyman Rapaport; Andrew Mellor; Peter Buckley
Journal:  Brain Behav Immun       Date:  2014-12-24       Impact factor: 7.217

Review 7.  An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists.

Authors:  Aniyizhai Annamalai; Cenk Tek
Journal:  Int J Endocrinol       Date:  2015-03-23       Impact factor: 3.257

8.  Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial.

Authors:  Cenk Tek; Sinan Guloksuz; Vinod H Srihari; Erin L Reutenauer
Journal:  BMC Psychiatry       Date:  2013-06-27       Impact factor: 3.630

9.  The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis.

Authors:  Jojanneke Bruins; Frederike Jörg; Richard Bruggeman; Cees Slooff; Eva Corpeleijn; Marieke Pijnenborg
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

Review 10.  Smoking Use and Cessation Among People with Serious Mental Illness.

Authors:  Aniyizhai Annamalai; Noreen Singh; Stephanie S O'Malley
Journal:  Yale J Biol Med       Date:  2015-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.